| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
| Targets |
Nampt activator-1 targets nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD+ salvage pathway. NAMPT catalyzes the conversion of nicotinamide to nicotinamide mononucleotide (NMN), a precursor of NAD+. By activating NAMPT with an EC50 of 3.3-3.7 μM, Nampt activator-1 increases NAD+ levels, which are essential for cellular energy metabolism, DNA repair, and sirtuin activity.
|
|---|---|
| ln Vitro |
In vitro, Nampt activator-1 is a potent activator of NAMPT with an EC50 of 3.3-3.7 μM. It increases NAMPT activity and promotes NAD+ synthesis. Nampt activator-1 is used in metabolic, aging, and neurobiology research.
|
| ln Vivo |
In vivo data for Nampt activator-1 is not extensively reported in publicly available sources. As a NAMPT activator that promotes NAD+ synthesis, the compound has potential applications in animal models of metabolic disorders, aging, and neurodegenerative diseases. By boosting NAD+ levels, Nampt activator-1 could improve cellular resilience and stress responses. However, specific published in vivo efficacy studies are not detailed in the current literature.
|
| Enzyme Assay |
The in vitro NAMPT activity assay for Nampt activator-1 uses recombinant NAMPT enzyme and its substrates nicotinamide and ATP. Enzyme activity is measured by quantifying the production of nicotinamide mononucleotide (NMN) using HPLC or mass spectrometry. EC50 values are calculated from dose-response curves. NAD+ levels are measured in cells treated with the compound.
|
| Cell Assay |
Cellular assays for Nampt activator-1 are conducted in various cell lines. Cells are treated with varying concentrations of Nampt activator-1. NAD+ levels are measured using enzymatic cycling assays or HPLC. Cell viability and proliferation are measured using standard assays such as MTT or CellTiter-Glo. The compound's effects on sirtuin activity and mitochondrial function are assessed.
|
| Animal Protocol |
In vivo studies for Nampt activator-1 would typically involve animal models of metabolic disorders, aging, or neurodegenerative diseases. The compound would be administered via intraperitoneal or oral routes. Efficacy would be assessed by measuring NAD+ levels, metabolic parameters, or cognitive function. However, specific published in vivo protocols for Nampt activator-1 are not available in the current literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Nampt activator-1 is not extensively reported. The compound has a molecular weight of 299.32 g/mol and a molecular formula of C16H17N3O3. It has a CAS number of 701929-65-9. As a small molecule, it is expected to have moderate bioavailability. Detailed PK parameters such as half-life and bioavailability are not available.
|
| Toxicity/Toxicokinetics |
Toxicity data for Nampt activator-1 is limited. As a research compound, Nampt activator-1 is intended for research use only and not for human therapeutic applications. Standard in vitro cytotoxicity assays and in vivo tolerability studies would be required for a complete toxicity assessment.
|
| References | |
| Additional Infomation |
Nampt activator-1 (CAS 701929-65-9) is a potent activator of NAMPT with an EC50 of 3.3-3.7 μM. It promotes NAD+ synthesis and is used in metabolic and aging research. It has a molecular formula of C16H17N3O3 and a molecular weight of 299.32 g/mol. Nampt activator-1 is for research use only.
|
| Molecular Formula |
C16H17N3O3
|
|---|---|
| Molecular Weight |
299.324483633041
|
| Exact Mass |
299.126
|
| CAS # |
701929-65-9
|
| PubChem CID |
969968
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.6
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
22
|
| Complexity |
362
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(OCC)(=O)C1=CC=C(NC(NCC2C=CN=CC=2)=O)C=C1
|
| InChi Key |
LNIPYBUMGBKFKQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H17N3O3/c1-2-22-15(20)13-3-5-14(6-4-13)19-16(21)18-11-12-7-9-17-10-8-12/h3-10H,2,11H2,1H3,(H2,18,19,21)
|
| Chemical Name |
ethyl 4-(pyridin-4-ylmethylcarbamoylamino)benzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~835.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3409 mL | 16.7045 mL | 33.4091 mL | |
| 5 mM | 0.6682 mL | 3.3409 mL | 6.6818 mL | |
| 10 mM | 0.3341 mL | 1.6705 mL | 3.3409 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
